This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
by Zacks Equity Research
Novo Nordisk beats Q4 earnings and sales estimates, but shares slide after management forecasts a 5-13% decline in 2026 sales and operating profit.
NVONegative Net Change LLYNegative Net Change ALKSNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook
by Zacks Equity Research
GSK's Q4 earnings and sales top estimates as strong specialty medicine demand fuels growth and drives shares higher on an upbeat 2026 outlook.
GSKPositive Net Change JNJPositive Net Change IONSNegative Net Change SPROPositive Net Change
biotechs earnings medical pharmaceuticals
Markets Rotate Back Out of Tech, Q4 Earnings After the Close
by Mark Vickery
Trading sagged mid-day, but only after the Dow hit a new intra-day high.
AMDNegative Net Change ADPNegative Net Change AMGNPositive Net Change CMGNegative Net Change
biotechnology biotechs earnings restaurants semiconductor tech-stocks
Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study
by Zacks Equity Research
SNY's phase III LEAP2MONO study meets all primary endpoints, with venglustat improving neurological symptoms in type 3 Gaucher disease patients.
SNYNegative Net Change ALKSNegative Net Change ASRTNegative Net Change CSTLNegative Net Change
biotechs
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
by Ekta Bagri
BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.
BMYPositive Net Change JNJPositive Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Silver Economy Boom: Investing in Healthcare's Aging Tailwinds
by Urmimala Biswas
An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.
ABTPositive Net Change BSXPositive Net Change AMGNPositive Net Change MDTPositive Net Change RMDPositive Net Change ABBVPositive Net Change
biotechs cancer healthcare hospitals medical medical-devices pharmaceuticals
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study
by Zacks Equity Research
Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes study, with no weight-loss plateau.
REGNNegative Net Change NVONegative Net Change ALKSNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
by Ahan Chakraborty
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
PCRXNegative Net Change ZTSPositive Net Change ACADNegative Net Change DNLINegative Net Change APLSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Here's Why Gilead Sciences Stock Surged 21% in a Month
by Zacks Equity Research
GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.
REGNNegative Net Change MRKPositive Net Change ALKSNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.
VRTXNegative Net Change MRNANegative Net Change CRSPNegative Net Change CSTLNegative Net Change
biotechs cell-therapy crispr gene-editing gene-therapy medical pharmaceuticals